Calocurb

What Calocurb does

Calocurb is a New Zealand-based dietary supplement company, founded in 2018 and headquartered in Auckland, that commercializes Amarasate®, a patented bitter hops extract (Humulus lupulus L.) developed over 15 years with NZ$30 million in research by Plant & Food Research, a New Zealand Crown Research Institute. The core product, Calocurb GLP-1 Activator, is a 100% plant-based capsule using Lonza® delayed-release technology that releases in the upper intestine, where the extract activates bitter taste receptors on gut enteroendocrine cells to trigger release of GLP-1, CCK, and PYY satiety hormones. Three peer-reviewed human clinical trials report a 30% reduction in hunger, 40% reduction in cravings, and 18% reduction in calorie intake within one hour of dosing; the company cites up to a 640% increase in GLP-1 levels and 6x elevation in gut peptide hormones. Calocurb positions its product as a natural, prescription-free, and affordable alternative to injectable GLP-1 medications such as Ozempic and Wegovy.

The company sells primarily through direct-to-consumer e-commerce (calocurb.co.nz) on a subscription model offering a 15% recurring discount, with the standard 90-capsule bottle priced at NZD $89.95 and a multi-bottle $5/bottle discount. A secondary practitioner/wholesale channel operates through wholesale.calocurb.com targeting healthcare professionals. In October 2025, Calocurb launched Calocurb Clinical at US$119.99, a higher-strength practitioner-only SKU, via an exclusive US distribution partnership with Ortho Molecular Products, with management stating a goal to double revenue and profit within one year. The company ships from a New Zealand fulfillment center to New Zealand, Australia, the United States, and South Africa, claims 10,000+ users, holds Kosher and GRAS certifications, and operates with 1-10 employees. Leadership includes founder and CEO Sarah Kennedy and chief marketing and growth officer Louise Cunningham; disclosed funding totals approximately NZ$188,562 across grants and an angel round.

Name

Calocurb

Legal name

Calocurb

Website

https://calocurb.co.nz

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Calocurb is a New Zealand-based dietary supplement company commercializing Amarasate®, a patented hops extract clinically shown to activate natural GLP-1 release and reduce appetite, sold direct-to-consumer and via US healthcare practitioners as a natural alternative to GLP-1 injectables.

Ownership category

akta.pro rank

Product category

Weight Management Dietary Supplements

NAICS

Food (Health) Supplement Retailers (456191)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Herbal & Botanical Supplements (CRADAGAD)

akta.pro secondary industry

Delivery Systems & Encapsulation (Microencapsulation, Liposomes, Emulsions, Beadlets, Spray-Dried) (AFAJAKAL)

Keywords

• Appetite control supplement
• Weight management supplement
• Plant-based dietary supplement
• Natural hunger support
• Bitter hops extract

Headquarters

HQ city

Auckland

HQ country

New Zealand

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Marketing or Sales, Technology or R&D, Operations, Personnel

Revenue model

1. Direct E-commerce Sales: Calocurb sells directly to consumers through its website (calocurb.co.nz) with both one-time purchases and subscription options. The subscription model offers 15% recurring discount and generates predictable recurring revenue.
2. Wholesale/Practitioner Channel: Sales to healthcare practitioners and through wholesale channels, including dedicated practitioner portal (wholesale.calocurb.com). New partnership with Ortho Molecular for US practitioner distribution.
3. Calocurb Clinical (Practitioner-Only Product): Higher-strength product Calocurb Clinical launched exclusively through licensed practitioners at US$119.99, targeting the professional healthcare channel in the US market.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Calocurb manufactures and sells a 100% plant-based appetite control capsule featuring Amarasate®, a patented hops extract that activates natural GLP-1 release. The core product (Calocurb GLP-1 Activator) is sold direct-to-consumer through the company's e-commerce site with subscription options, while a higher-strength Calocurb Clinical variant is distributed exclusively through licensed healthcare practitioners via a US partnership with Ortho Molecular Products. The product is positioned as a natural, prescription-free, $1-per-capsule alternative to injectable GLP-1 weight-loss medications.

Product overview

Calocurb offers a portfolio of natural appetite control supplements centered on its patented Amarasate hops extract. The core product, Calocurb GLP-1 Activator, is a 100% plant-based capsule that triggers natural GLP-1 hormone release to reduce hunger and cravings. Calocurb Clinical is a higher-strength variant launched in October 2025 exclusively through licensed practitioners in the US market. Both products leverage the same Amarasate technology validated in peer-reviewed human clinical trials.

Differentiator

Problem solved

Functional benefit

Brands

• Calocurb Clinical: A stronger, clinically proven appetite management supplement launched in partnership with Ortho Molecular Products, priced at US$119.99 for practitioners.

Products and services

• Calocurb GLP-1 Activator A 100% natural appetite control supplement featuring Amarasate®, a patented hops extract. Clinically shown to reduce hunger by 30%, cravings by 40%, and calorie intake by 18% within one hour. Taken as capsules before meals to naturally activate GLP-1 hormone for individual consumers seeking weight management.
• Calocurb Clinical A stronger, clinically proven appetite management supplement containing Amarasate® extract, available exclusively under the guidance of licensed healthcare practitioners. Priced at US$119.99 per bottle. Launched October 2025 in the US market via the Ortho Molecular Products distribution partnership.

Quantifiable outcome

• 30% reduction in hunger within one hour
• +4 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Ortho Molecular ProductscoreChannel Partner/ Reseller/ Distributor · 1 October 2025Ortho Molecular Products, a nutraceutical manufacturer in the United States, partnered with Calocurb to launch Calocurb CLINICAL in October 2025. The partnership targets licensed practitioners as the distribution channel, offering the higher-strength clinical product exclusively under practitioner guidance. Calocurb aims to double its revenue and profit within a year through this US market expansion.

Scale indicators6 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Zotrim: Zotrim is a herbal-based appetite suppressant supplement sold globally online, founded and branded around 'feel fuller longer.' It is a direct comparable to Calocurb as an OTC, plant-derived capsule targeting food cravings and portion control, with a similar DTC subscription model.
• PhenQ: PhenQ is a multi-ingredient over-the-counter weight management supplement sold direct-to-consumer online. It competes in the same 'natural, non-prescription, multi-action' appetite/weight-loss category and relies on similar content/affiliate marketing, making it a direct comparable for customer acquisition dynamics.
• Leanbean: Leanbean is a DTC, capsule-based 'natural appetite suppressant' marketed heavily via influencer affiliates, similar in form, audience, and funnel to Calocurb's GLP-1 Activator. Both target women-focused appetite/weight-loss use cases through education-driven content marketing.

Broad incumbents

• Hydroxycut: Hydroxycut is one of the most-recognized legacy OTC weight-loss supplement brands in mass retail. It competes with Calocurb for the same weight-loss shopper but operates at significantly broader scale, distribution, and marketing budget — making it a broad incumbent rather than a niche peer.
• Alli (GSK): Alli is the only FDA-approved over-the-counter weight-loss product (orlistat), sold by GSK in retail pharmacies. It competes for the same OTC weight-management consumer but with a clinically regulated pharmaceutical positioning rather than a botanical one, making it a broad incumbent/comparator on positioning.
• Himalaya Wellness: Himalaya Wellness is a global botanical/herbal supplement and personal-care company with deep roots in clinically-studied plant extracts. While much larger and broader in portfolio, it is comparable to Calocurb on the supply of standardized herbal ingredients and the credibility signal of clinical studies on botanicals.
• Nature's Way: Nature's Way is an established herbal and supplement brand with mass-market retail distribution. It is a broad incumbent adjacent peer — competing for the same shelf-share and consumer mindshare for herbal weight-management and digestive health products, but at much greater scale and broader category breadth.

Emerging players

• Hers (Hims & Hers Health): Hers sells OTC weight-management products and telehealth-prescribed GLP-1 medications directly to consumers through its online platform. It overlaps with Calocurb in the addressable market of consumers seeking non-injection, app-accessible weight-loss solutions, but distributes across both supplements and prescriptions.
• Ro: Ro's direct-to-consumer platform now includes branded GLP-1 and compounded obesity care, competing head-on for the consumer who would otherwise be a Calocurb customer. It is an emerging peer in the convergence of telehealth, GLP-1 supply, and adjacent supplements.
• Gaia Herbs: Gaia Herbs is a premium botanical/herbal supplement brand with a heavy emphasis on traceability, clinical evidence, and practitioner recommendations. It is comparable to Calocurb on the 'clinically-evidenced botanical supplement' positioning and the practitioner/recommendation channel, but operates a much broader SKU range.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/calocurbglobal
• Instagraminstagram.com/calocurb
• Xx.com/calocurb

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Calocurb